Norsk selskap for hematologi

2019

Norwegian Myeloma Workshop 17.-18. oktober '19

Kjære kolleger

Den 17.-18. oktober 2019 arrangeres for 2. gang Norwegian Myeloma Workshop i Trondheim. Dette er et møte hvor vi diskuterer myelomatoseforskning. Vi har et spennende program til årets møte som dere ser under. Informasjon og påmelding finner du her: https://www.eventsforce.net/firstunited/14/home?language=7


Med vennlig hilsen


Fredrik Schjesvold og Tobias Slørdahl



12. september 2019

 

Program for the 2nd Norwegian Myeloma Workshop –

Clarion Hotel Brattøra, Trondheim 17.-18. October

 

Thursday 17th of October

 

12:00 - 13:00         Lunch

13:00 – 13:15        Opening
Tobias Slørdahl & Fredrik Schjesvold

13:15 – 13:30        The REMNANT study team - Fredrik Schjesvold

13:30 – 14:30        The clinical outline and protocol questions to solve - Fredrik Schjesvold / Anne-Marie Rasmussen

14:30 – 14:45        Break

14:45 – 15:15        Budget overview and additional applications - Anne-Marie Rasmussen

15:15 – 16:15        Flow cytometry and biobanking - Mona Fenstad og Liv Osnes

16:15 – 16:30        Break

15:30 – 16:00        Additional research questions including QOL - pending funding - Anne-Marie Rasmussen

16:00 – 16:45        Formalities of the national collaboration - Contracts and so on - Anne-Marie Rasmussen

16:45 - 17:15         Discussion 

17:15 - 17:30         Recap and conclusion - Fredrik Schjesvold

18:00                     Dinner

 

Friday 18th of October

 

08:00 – 08:30        TAK-inhibitors in myeloma
Kristian Starheim, NTNU

08:30 – 09:00        The journey from patient – preparation – storage and utilization – The organization of the Norwegian Myeloma Biobank – Biobank 1
Lill Anny Gunnes Grøseth, Biobank 1

09:00 – 10:30        Increasing the activity of bone morphogenetic proteins as a treatment strategy in multiple myeloma

                               Toril Holien PhD, NTNU

09:30 - 09:45         Break

09:45 –10:00         The Myeloma-HCQ study - Update
Tobias S. Slørdahl, NTNU/St. Olavs hospital

10:00 – 11:00        How can the pharmaceutical companies contribute in investigator initiated Norwegian Trials?
Knut Steffensen, Hilde Abrahamsen and Hege Riisa. Discussion

11:00 – 11:15        Break

11:15 – 11:45        Immunotherapy targeting a tumor-associated ganglioside [No industry]
Anders Tveita, Oslo University Hospital

11:45 – 12:00        Update on MRD in myeloma
Mona Fenstad, St. Olavs hospital

12:00 - 12:30         Små sykehus og kliniske studier – Hvordan best delta?
Diskusjon med innledning av Jon Hjalmar Sørbø, Levanger sykehus

12:30 – 13:00        Discussions on cooperation and conclusions

13:00                      Lunch and goodbye